1359 BROADWAY, SUITE 801, NEW YORK, NY
Market cap: $173.4M (2/09/2026)
Price: $2.40
Investor Presentation
Material disclosure
Financial Results, Reg. FD
Changes in Board, Management or Compensation, Reg. FD
Reports Second Quarter 2025 Financial Results and Operational Progress
Shareholder votes
Phase 1 Study of Azenosertib in Combination with Encorafenib and Cetuximab for Metastatic CRC
News
Q3
Q2
Q1
FY 2024
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload